BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 19169274)

  • 41. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
    Flis S; Gnyszka A; Spławiński J
    Biochem Biophys Res Commun; 2009 Sep; 387(2):336-41. PubMed ID: 19596269
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
    Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
    Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity.
    Mai A; Valente S; Rotili D; Massa S; Botta G; Brosch G; Miceli M; Nebbioso A; Altucci L
    Int J Biochem Cell Biol; 2007; 39(7-8):1510-22. PubMed ID: 17482499
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting histone deacetylase in cancer therapy.
    Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
    Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.
    Yan C; Xiu Z; Li X; Li S; Hao C; Teng H
    Proteins; 2008 Oct; 73(1):134-49. PubMed ID: 18398905
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms of HDAC inhibitor-induced thrombocytopenia.
    Matsuoka H; Unami A; Fujimura T; Noto T; Takata Y; Yoshizawa K; Mori H; Aramori I; Mutoh S
    Eur J Pharmacol; 2007 Oct; 571(2-3):88-96. PubMed ID: 17628529
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity.
    Mai A; Massa S; Cerbara I; Valente S; Ragno R; Bottoni P; Scatena R; Loidl P; Brosch G
    J Med Chem; 2004 Feb; 47(5):1098-109. PubMed ID: 14971890
    [TBL] [Abstract][Full Text] [Related]  

  • 48. N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
    Wang H; Yu N; Song H; Chen D; Zou Y; Deng W; Lye PL; Chang J; Ng M; Sun ET; Sangthongpitag K; Wang X; Wu X; Khng HH; Fang L; Goh SK; Ong WC; Bonday Z; Stünkel W; Poulsen A; Entzeroth M
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1403-8. PubMed ID: 19181524
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
    Zhang Y; Feng J; Liu C; Zhang L; Jiao J; Fang H; Su L; Zhang X; Zhang J; Li M; Wang B; Xu W
    Bioorg Med Chem; 2010 Mar; 18(5):1761-72. PubMed ID: 20171895
    [TBL] [Abstract][Full Text] [Related]  

  • 50. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
    Remiszewski SW; Sambucetti LC; Bair KW; Bontempo J; Cesarz D; Chandramouli N; Chen R; Cheung M; Cornell-Kennon S; Dean K; Diamantidis G; France D; Green MA; Howell KL; Kashi R; Kwon P; Lassota P; Martin MS; Mou Y; Perez LB; Sharma S; Smith T; Sorensen E; Taplin F; Trogani N; Versace R; Walker H; Weltchek-Engler S; Wood A; Wu A; Atadja P
    J Med Chem; 2003 Oct; 46(21):4609-24. PubMed ID: 14521422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
    Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
    Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
    Johnstone RW
    Nat Rev Drug Discov; 2002 Apr; 1(4):287-99. PubMed ID: 12120280
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.
    Andrews DM; Stokes ES; Carr GR; Matusiak ZS; Roberts CA; Waring MJ; Brady MC; Chresta CM; East SJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2580-4. PubMed ID: 18378449
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
    Jaboin J; Wild J; Hamidi H; Khanna C; Kim CJ; Robey R; Bates SE; Thiele CJ
    Cancer Res; 2002 Nov; 62(21):6108-15. PubMed ID: 12414635
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs).
    Schäfer S; Saunders L; Eliseeva E; Velena A; Jung M; Schwienhorst A; Strasser A; Dickmanns A; Ficner R; Schlimme S; Sippl W; Verdin E; Jung M
    Bioorg Med Chem; 2008 Feb; 16(4):2011-33. PubMed ID: 18054239
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
    Rahim R; Strobl JS
    Anticancer Drugs; 2009 Sep; 20(8):736-45. PubMed ID: 19584707
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors.
    Mai A; Massa S; Rotili D; Simeoni S; Ragno R; Botta G; Nebbioso A; Miceli M; Altucci L; Brosch G
    J Med Chem; 2006 Oct; 49(20):6046-56. PubMed ID: 17004718
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
    Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
    ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.